

flavorings. Each milliliter contains erythromycin estolate equivalent to 25 milligrams of erythromycin and 120 milligrams of sulfisoxazole. Its erythromycin content is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of erythromycin that it is represented to contain. Its sulfisoxazole acetyl content is satisfactory if it is not less than 90 percent and not more than 115 percent of the number of milligrams of sulfisoxazole that it is represented to contain. Its pH is not less than 3.5 and not more than 6.5. The erythromycin estolate used conforms to the standards prescribed by § 452.15(a)(1). The sulfisoxazole acetyl used conforms to the standards prescribed by the U.S.P. XXII.

(2) *Labeling.* It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples.* In addition to complying with the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(A) The erythromycin estolate used in making the batch for potency, moisture, pH, crystallinity, and identity.

(B) The sulfisoxazole acetyl used in making the batch for all U.S.P. XXII specifications.

(C) The batch for erythromycin content, sulfisoxazole content, and pH.

(ii) Samples, if required by the Center for Drug Evaluation and Research:

(A) The erythromycin estolate used in making the batch: 10 packages, each containing not less than 500 milligrams.

(B) The batch: a minimum of 15 immediate containers.

(b) *Tests and methods of assay—(1) Erythromycin content.* Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Remove an accurately measured representative volume of the suspension and dilute with sufficient methyl alcohol to give a concentration of 2.5 milligrams per milliliter (estimated). Dilute the entire mixture with sufficient 0.1M potassium phosphate buffer, pH 8.0 (solution 3), to give a concentration of 1.0 milligram of erythromycin base per milliliter (estimated). Hydrolyze in a 60 °C constant temperature water bath

for 2 hours or at room temperature for 16 to 18 hours. Further dilute with solution 3 to the reference concentration of 1.0 microgram of erythromycin base per milliliter (estimated).

(2) *Sulfisoxazole content.* Proceed as directed in § 436.328 of this chapter.

(3) *pH.* Proceed as directed in § 436.202 of this chapter, using the drug as it is prepared for dispensing.

[55 FR 280, Jan. 4, 1990]

**§ 452.125 Erythromycin ethylsuccinate oral dosage forms.**

**§ 452.125a Erythromycin ethylsuccinate chewable tablets.**

(a) *Requirements for certification—(1) Standards of identity, strength, quality, and purity.* Erythromycin ethylsuccinate chewable tablets are composed of erythromycin ethylsuccinate and suitable and harmless diluents, binders, buffers, colorings, and flavorings. Each tablet contains erythromycin ethylsuccinate equivalent to 200 milligrams of erythromycin. Its potency is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of erythromycin that it is represented to contain. The moisture content is not more than 5 percent. The erythromycin ethylsuccinate used conforms to the standards prescribed by § 452.25(a)(1).

(2) *Labeling.* In addition to the labeling requirements prescribed by § 432.5 of this chapter, this drug shall be labeled "erythromycin ethylsuccinate tablets".

(3) *Requests for certification; samples.* In addition to the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The erythromycin ethylsuccinate used in making the batch for potency, moisture, pH, residue on ignition, identity, and crystallinity.

(b) The batch for potency and moisture.

(ii) Samples required:

(a) The erythromycin ethylsuccinate used in making the batch: 10 packages, each consisting of 500 milligrams.

(b) The batch: A minimum of 36 tablets.

(b) *Tests and methods of assay*—(1) *Potency*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Blend a representative number of tablets in a high-speed glass blender for 2 to 3 minutes with 200 milliliters of methyl alcohol. Add 300 milliliters of 0.1M potassium phosphate buffer, pH 8.0 (solution 3), and blend again for 2 to 3 minutes. Further dilute with solution 3 to the reference concentration of 1.0 microgram of erythromycin base per milliliter (estimated).

(2) *Moisture*. Proceed as directed in § 436.201 of this chapter.

[39 FR 19149, May 30, 1974, as amended at 41 FR 51596, Nov. 23, 1976; 42 FR 29858, June 10, 1977; 50 FR 19921, May 13, 1985]

**§ 452.125b Erythromycin ethylsuccinate oral suspension.**

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*. Erythromycin ethylsuccinate oral suspension is erythromycin ethylsuccinate with suitable and harmless buffer substances, dispersing agents, diluents, colorings, flavorings, and preservatives. Each milliliter contains erythromycin ethylsuccinate equivalent to 40 or 80 milligrams of erythromycin. Its potency is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of erythromycin that it is represented to contain. Its pH is not less than 6.5 and not more than 8.5. The erythromycin ethylsuccinate used conforms to the standards prescribed by § 452.25(a)(1).

(2) *Labeling*. It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples*. In addition to the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The erythromycin ethylsuccinate used in making the batch for potency, moisture, pH, identity, residue on ignition, and crystallinity.

(b) The batch for potency and pH.

(ii) Samples required:

(a) The erythromycin ethylsuccinate used in making the batch: 10 containers each consisting of 500 milligrams.

(b) The batch: A minimum of 5 immediate containers.

(b) *Tests and methods of assay*—(1) *Potency*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Place an accurately measured representative volume of the suspension into a high-speed glass blender jar and add sufficient methyl alcohol to give a concentration of 1.0 milligram of erythromycin base per milliliter (estimated). Blend for 3 to 5 minutes. Further dilute with 0.1M potassium phosphate buffer, pH 8.0 (solution 3), to the reference concentration of 1.0 microgram of erythromycin base per milliliter (estimated).

(2) *pH*. Proceed as directed in § 436.202 of this chapter, using the undiluted drug.

[39 FR 19149, May 30, 1974, as amended at 50 FR 19921, May 13, 1985]

**§ 452.125c Erythromycin ethylsuccinate for oral suspension.**

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*. Erythromycin ethylsuccinate for oral suspension is a dry mixture of erythromycin ethylsuccinate with suitable and harmless buffer substances, dispersing agents, diluents, colorings, and flavorings. It contains the equivalent of 40 milligrams or 80 milligrams of erythromycin per milliliter of the reconstituted suspension. Its potency is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of erythromycin that it is represented to contain. Its loss on drying is not more than 1 percent. When reconstituted as directed in the labeling, its pH is not less than 7.0 nor more than 9.0. The crystalline erythromycin ethylsuccinate used conforms to the standards prescribed by § 452.25(a)(1).

(2) *Labeling*. It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples*. In addition to the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The erythromycin ethylsuccinate used in making the batch for potency,